The circulating T cell senescence immune phenotype (CD28−CD57+KLRG1+) has been observed in 28% of patients with advanced NSCLC and is associated with a significantly poorer objective response rate, PFS, and OS after ICI treatment43. Here, KLRG1 is linked to non-small cell lung carcinoma.